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OBJECTIVES: In this study, we aimed to determine the complications of standard surgical treatments among patients
over 75 years in a high-volume urologic center.
METHODS: We analyzed 100 consecutive patients older than 75 years who had undergone transurethral prostatic
resection of the prostate or open prostatectomy for treatment of benign prostatic hyperplasia from January 2008 to
March 2010. We analyzed patient age, prostate volume, prostate-specific antigen level, international prostatic
symptom score, quality of life score, urinary retention, co-morbidities, surgical technique and satisfaction with
treatment.
RESULTS: Median age was 79 years. Forty-eight patients had undergone transurethral prostatic resection of the
prostate, and 52 had undergone open prostatectomy. The median International Prostatic Symptom Score was 20,
the median prostate volume was 83 g, 51% were using an indwelling bladder catheter, and the median prostate-
specific antigen level was 5.0 ng/ml. The most common comorbidities were hypertension, diabetes and coronary
disease. After a median follow-up period of 17 months, most patients were satisfied. Complications were present in
20% of cases. The most common urological complication was urethral stenosis, followed by bladder neck sclerosis,
urinary fistula, late macroscopic hematuria and persistent urinary incontinence. The most common clinical
complication was myocardial infarction, followed by acute renal failure requiring dialysis. Incidental carcinoma of
the prostate was present in 6% of cases. One case had urothelial bladder cancer.
CONCLUSIONS: Standard surgical treatments for benign prostatic hyperplasia are safe and satisfactory among the
elderly. Complications are infrequent, and urethral stenosis is the most common. No clinical variable is associated
with the occurrence of complications.
KEYWORDS: Prostatic Hyperplasia; Prostatectomy; Transurethral Resection of Prostate; Aged; Quality of Life,
Complications.
Marmiroli R, Antunes AA, Reis ST, Nakano E, Srougi M. Standard surgical treatment for benign prostatic hyperplasia is safe for patients over 75 years:
Analysis of 100 cases from a high-volume urologic center. Clinics. 2012;67(12):1415-1418.
Received for publication on June 12, 2012; First review completed on July 26, 2012; Accepted for publication on August 20, 2012
E-mail: antunesuro@uol.com.br
Tel.: 55 11 3255-6372
INTRODUCTION
Benign prostatic hyperplasia (BPH) represents an increase
in the total number of stromal and epithelial cells within the
prostate gland. It is associated with bothersome lower
urinary tract symptoms that affect the individual’s quality
of life and interfere with day-to-day activities. BPH is now
one of the most common diseases in the elderly. According
to histological studies, more than 50% of men will face this
diagnosis by the age of 60 (90% by the age of 85) (1).
Assuming that by the year 2030, 20% of the population of
the United States will be older than 65 years (2), the rise in the
incidence of lower urinary tract symptoms (LUTS) due to
BPH makes it a public health question. LUTS involve an
estimated annual impact of $1.1 billion of direct costs
(excluding outpatient pharmaceuticals) and indirect costs of
approximately 38 million hours of lost productivity by these
patients (3).
In recent decades, several new methods for treating BPH
have been developed, both pharmaceutical and surgical.
Several minimally invasive procedures are still favored by
the international community due to their lower complica-
tion rates. However, it is necessary to remember that the
perceived efficacy and long-term durability of these
therapies remain to be proven; so far, the gold-standard
treatments are still open prostatectomy (OP) and transure-
thral resection of the prostate (TURP) (4).
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Because BPH is associated with old age, OP and TURP are
usually performed in patients with various comorbidities.
Some studies have confirmed a direct effect of comorbidity
on perioperative morbidity and mortality after these
procedures (5,6). However, OP and TURP patient popula-
tions, especially in multicenter studies and meta-analyses
with large numbers of patients, are generally approximately
65 to 75 years old (7,8).
A better understanding of the clinical characteristics of
patients over 75 years old is important for preventing
complications and improving clinical outcomes. In this
study, we aimed to determine the complications (both clinical
and urological) of standard surgical treatments among
patients over 75 years in a high-volume urologic center.
MATERIALS AND METHODS
We analyzed a selected group of 100 consecutive patients
older than 75 years who had undergone TURP or OP for
BPH from January 2008 to March 2010.
Exclusion criteria in this study were previous surgical
treatment for BPH, diagnosis of prostate cancer and
suspected neurogenic bladder. Preoperatively, all patients
were subjected to anamnesis focused on urinary symptoms,
according to the International Prostate Symptom Score
(IPSS) and QOL (Quality Of Life) gradation. We also
analyzed the available information from digital rectal
examinations, prostate ultrasounds, prostate-specific anti-
gen (PSA) levels, use of an indwelling bladder catheter due
to urinary retention, presence of co-morbidities (arterial
hypertension, diabetes and coronary diseases) and surgical
technique. To analyze treatment outcome, patients were
asked if they were satisfied with the treatment results.
Urologic and non-urologic complications were recorded.
It is important to note that all patients preoperatively
attended an evaluation with specialists; patients who were
considered to be at high risk of complications (cardiological
or other) after an analysis of their global health status and
comorbidities were not treated with surgery.
Statistical analysis was performed using SPSSH 19.0
software for WindowsH (IBM Incorporated, Armonk, New
York), and significance was defined as p,0.05. All data are
presented as median (range) unless specified otherwise. We
determined the risk factors for complications using the chi-
square and Student’s-t tests.
RESULTS
The median patient age was 79 years (75 to 91). Forty-
eight patients were subjected to TURP and 52 to OP.
Hypertension, diabetes and coronary disease were present
in 69%, 24% and 26% of the cases, respectively.
Median preoperative IPSS was 20 (8 to 31), and 51% of
patients were using an indwelling bladder catheter. Median
prostate volume was 83 g (24 to 417), and median PSA level
was 5.0 ng/ml (0.2 to 60). After a median follow-up period of
17 months (1 to 40), 83% of patients were satisfied with the
treatment.
Overall, complications were present in 20% of cases.
Regarding urological complications, 10% presented urethral
stenosis, 2% had bladder neck sclerosis, 2% had urinary fistula,
2% had late macroscopic hematuria and 2% had persistent
urinary incontinence. Among clinical complications, 1% pre-
sented acute renal failure requiring dialysis, and 2% presented
myocardial infarction. One patient died due to infarction.
Incidental carcinoma of the prostate was present in 6%
of cases (5% T1a and 1% T1b). One case had incidental
urothelial bladder cancer. Even though patients who
presented complications had larger prostates, higher PSA
levels and higher rates of hypertension, diabetes and
coronary disease, no variable was statistically associated
with the occurrence of complications (Table 1).
DISCUSSION
This study demonstrates that traditional surgical treat-
ments for BPH can be performed in patients older than 75
years with acceptable complication rates and good func-
tional results. No variable was statistically associated with
the occurrence of complications; therefore, no comorbidity
taken alone can be considered an absolute contra-indication
for these procedures.
With the increase in the number of aging males in most
populations, an improved understanding of the clinical
characteristics of this selected population is important for
improving surgical outcomes. On average, patients with
BPH who are candidates for surgical treatment are older
than before. Choi et al. (18) compared the characteristics of
patients who underwent surgery in 1985 to 1989, in 1995 to
1999 and in 2005 to 2009. The mean ages of the men were
65.4, 65.9 and 69.3 years, respectively. Likewise, the
prevalence of hypertension, a history of surgery, and "other
complications" (e.g., stroke, cancer and cardiac conditions)
increased significantly over time. The prevalence of hyper-
tension increased from 22% in the first period to 43% in the
last, and the prevalence of diabetes increased from 8% to
13%.
Due to the relative morbidity of TURP and OP, minimally
surgical alternatives have been proposed for the treatment
of BPH. Among these alternatives, transurethral needle
ablation of the prostate with radiofrequency and transure-
thral microwave thermotherapy (TUMT) have been fre-
quently performed in the United States. Their main
advantage is the fact that they are performed under local
anesthesia in an outpatient fashion. However, systematic
reviews of the literature have concluded that they do not
achieve the same level of efficacy as the classic methods
with respect to any subjective or objective variable. Further,
their efficacy declines in the long term, with a significantly
higher rate of secondary treatment than encountered with
classic methods [20-22].
Table 1 - Patient characteristics according to the incidence
of complications.
Complications
(n= 20)
No complications
(n= 80) p-value
Age (years) 79.3 79.7 0.72
IPSS 15.8 19.6 0.14
QoL score 4.1 4.1 0.86
Prostate volume (g) 124.8 92.2 0.20
PSA (ng/ml) 8.8 7.8 0.66
Urinary retention 55% 52% 0.80
Hypertension 80% 66% 0.23
Diabetes 30% 22% 0.48
Coronary disease 40% 22% 0.11
Surgery 0.42
TURP 17% 83%
OP 23% 77%
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Laser therapies are also surgical alternatives that might be
considered for high-risk surgical patients. Among these, the
photoselective vaporization of the prostate with the
GreenLight laser and holmium laser enucleation of the
prostate are the two most performed methods. Both
techniques are associated with shorter catheter time and
hospital stay. Studies with a longer follow-up are necessary
to establish the role of laser techniques in the surgical
treatment of BPH.
Regarding patients’ expectations about prostate surgery,
Zwergel et al. (12), in a study with a follow-up of more than
15 years after TURP reported satisfaction rates of 79%
satisfied, 12% neutral, and 9% dissatisfied with their
micturition, which is similar to our data (83% satisfied).
Reich et al. (11), in a multicentric prospective evaluation
that involved 10,654 patients, reported a 27.5% rate of
preoperative catheterization. In our study, 51% of patients
were using an indwelling bladder catheter. This high rate
can be justified by our patients’ larger prostates and
previous acute urinary retention episodes. We think that
the issue of preoperative catheterization may be related not
only to public health and educational issues but also to
cultural barriers that lead to a delayed search for medical
help and, after receiving medical help, a delay in under-
going a proper urological evaluation.
The rates of urological complications in this study were
10% urethral stenosis, 2% bladder neck sclerosis, 2% urinary
fistula, 2% late macroscopic hematuria and 2% persistent
urinary incontinence. Varkarakis et al. (13), in a Greek study
that analyzed complications after OP in 232 patients,
identified long-term complications of bladder neck contrac-
tion in 3.3%, urethral strictures in 0.6% and meatal stenosis
in 1.3% of the patients. In the study by Ahyai et al,
consistent with our study, the most common urological late
complication was urethral stenosis, which they observed in
4.1% of patients.
Our co-morbidity rates are slightly higher than others. In
comparing our rates to the recent study of 1,878 patients by
Hammarsten and Hogstedt (8), we noted higher proportions
of patients with hypertension [69% vs. 46.1%], diabetes
(24% vs. 18.2%) and cardiac disorders (26% vs. 17%).
Additionally, with a median age of 79 years, our patients
were ten years older. Due in part to their younger and
healthier patients, Hammarsten and Hogstedt reported a
5.8% complication rate, which is quite lower than we found
(20%). Ahyai et al. (7), in a meta-analysis of 27 studies
(including 23 randomized controlled studies) with a total of
2,247 patients, reported an overall complication rate of
32.4%. In the consulted literature, postoperative death due
to coronary disease ranges from 0.05 to 1%. These rates are
consistent with our data.
No patient in our series developed postoperative urinary
incontinence. This finding is important because our group
previously demonstrated that patients older than 70 years
have twice the probability of post-procedural incontinence.
Additionally, the chances of bladder dysfunction, which
may be the isolated cause of incontinence in approximately
25% of patients, rises 5.3% for each year added to patient
age (20).
Incidental carcinoma of the prostate was found in 6% of
cases. (5% T1a and 1% T1b). Previous studies have reported
finding cancer in 7% to 14% of cases following non-
oncological surgery (16-18).
The relatively small number of patients included and the
lack of a control group of patients less than 65 years old are
known limitations of this study. It is also important to note
that the study only included men who were considered to
be adequate candidates for surgery after clinical evaluation.
This fact may constitute a possible selection bias, as the
complication rates were likely reduced because we did not
perform surgical therapy in patients with more adverse
clinical conditions.
According to the data presented in this study, complica-
tions are infrequent, and standard surgical treatments for
the treatment of BPH are safe for elderly patients. No
clinical variable was associated with the occurrence of
complications. In our study, most patients were satisfied
after surgery.
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